Chong Kun Dang said that the Ministry of Health of Ukraine has approved the company to conduct a phase 3 clinical trial of Covid-19 drug candidate, Nafabeltan (ingredient: nafamostat).Ukraine is the first foreign country to authorize Chong Kun Dang’s phase 3 study following the approval granted by t
Recent media reports about GC Pharma in talks with Janssen for a consigned agreement manufacturing Covid-19 vaccines have been revealed as rumors -- at least so far -- industry sources said Wednesday.The two companies acknowledged they had met but stopped short of providing detailed information over
Korea United Pharm took legal action to protect its patent of antitussive drug Levotics CR Tab. (levodropropizine) against generic copies.The company said on Tuesday that it filed a lawsuit against 15 generic drugmakers that allegedly infringed upon the patent of Levotics CR Tab.Korea United Pharm d
GC Labcell said that it has published a paper related to genetically engineered support cells, one of its culture platform technologies, in the latest issue of Cellular & Molecular Immunology.“This paper is about a unique technology for support cells that induce proliferation and activity of natural
Daewoong Pharmaceutical and Daiichi Sankyo Korea said they have found no azido methyl biphenyl tetrazole (AZBT) in 21 olmesartan drugs for high blood pressure during the recent inspection.The two companies performed the inspection following Health Canada's measure to recall treatments after detectin
AstraZeneca’s Lynparza tablet (ingredient: olaparib), a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, has become reimbursable for the first- and second-line maintenance therapy in ovarian cancer patients.The anticancer drug shifted its form from capsule to tablet and obtained health
Hanall Biopharma has begun administrating HL161 (ingredient: batoclimab) in phase 3 clinical trials conducted in China for treating myasthenia gravis. Harbour Biomed, Hanall Biopharm’s Chinese partner, is conducting clinical trials in patients with a rare long-term condition that causes muscle weakn
Local developers of Covid-19 vaccines have announced plans to conduct large-scale, late-stage global trials, raising expectations for homegrown Covid-19 vaccines.However, some companies have to overcome several challenges, and it will take some time to commercialize a local Covid-19 vaccine, observe
Daewon Pharmaceutical said that it found TG Fenon (Ingredient: fenofibrate choline) significantly reduces triglyceride levels, reaffirming its safety in phase 4 clinical trial of treating patients with hypertriglyceridemia.The company compared triglyceride reduction between patient groups that recei
Novartis’ CDK4/6 inhibitor Kisqali (ribociclib), combined with letrozole, extended overall survival by more than one year in patients with hormone receptor-positive, human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer.The company released the results of phase 3 MONALEESA-2 tr
The number of patients treated for heart diseases caused by myocardial ischemia sharply grew in Korea over the past five years, significantly increasing medical expenses for their treatment, data showed.According to the National Health Insurance Service, the number of patients with ischemic heart di
JW Creagene said Monday that it would cooperate with Oncoinsight to develop the next-generation anticancer cell therapy called CAR-M.Through this collaboration, the two companies will jointly research and develop a CAR-Macrophage (CAR-M). This anticancer cell therapy combines a chimeric antigen rece
The market competition of combination therapies for hypertension and dyslipidemia is likely to heat up, as Yuhan Corp. and JW Pharmaceutical recently won approval for related products.Prescriptions of dyslipidemia combo drugs jumped 21 percent on-year to 633.5 billion won ($536.7 million) in Korea i
Avastin (bevacizumab), a vascular endothelial growth factor (VEGF) inhibitor, is almost a staple in anticancer treatment combined with chemotherapy or immunotherapy in various types of cancer.After Samsung Bioepis’ biosimilar of Avastin became reimbursable in Korea, the government notified that it w
Homegrown antibody biosimilar products are accelerating their penetration into the global market, as two makers -- Samsung Bioepis and Celltrion – have scored 11 approvals in Europe and eight in the U.S.The achievement came eight years after Celltrion won the nod for Remsima (ingredient: infliximab)
Huons has signed an agreement with AriBio, a biotech firm specializing in medicines for neurodegenerative and infectious disease, to develop new brain disease and dementia drugs targeting the global market.The two partners signed an agreement to develop AriBio's treatment candidates for brain diseas
Yuhan Corp.’s new anti-cancer drug Leclaza (ingredient: lazertinib), in combination with Janssen’s Rybrevant (ingredient: amivantamab), raised the response rate and extended the duration of response in advanced non-small cell lung cancer (NSCLC) patients who failed previous treatment.Researchers pre
Despite the prolonging Covid-19 pandemic, many Korean biopharmaceutical companies took part in the 2021 European Society for Medical Oncology (ESMO) Congress, one of the largest cancer meetings globally, to present their development of pipelines.ESMO presents the latest scientific developments in ba
Access Bio signed an agreement with PharmGen Science and New Jersey’s IVY Pharma to jointly develop a biosimilar of Covid-19 mRNA vaccine as part of the global vaccine partnership between Korea and the U.S.Under the accord, Access Bio and PharmGen Science will co-invest in IVY Pharma’s research on c
Sanofi-Aventis Korea said Thursday that oral biologic Dupixent (ingredient: dupilumab) has reaffirmed its efficacy in improving the quality of life of severe asthma patients by preventing symptom exacerbations.The company presented its study results at a recent online meeting hosted by the European